Ximelagatran for the prophylaxis of various complications due to thrombosis

Canadian Coordinating Office for Health Technology Assessment
Record ID 32003001145
English, French
Authors' objectives:

To summarize the available information on ximelagatran (Exanta(TM) from AstraZeneca) for use in the treatment of venous thromboembolism (VTE), the prophylaxis of VTE in orthopedic surgery, the prophylaxis of stroke in patients with atrial fibrillation, and secondary prophylaxis in patients post-myocardial infarction.

Authors' results and conclusions: Several clinical trials have been undertaken to investigate the efficacy of ximelagatran in a variety of clinical situations (see objectives above). Few phase II and phase III trial results can be found in the published literature.
Authors' recomendations: Ximelagatran is the first oral direct thrombin inhibitor to proceed to late stage clinical development; very little progress has been made in recent history in regard to oral anticoagulation. The clinical trial program underway with this medication is extensive, with research in VTE treatment and research furthest along; the amount of published data available is relatively small, although trials have been conducted in over 20,000 patients. Generalizing findings may be difficult as there are subtle differences in the way anticoagulation is currently practised in the European and North American trial settings. The effect of ximelagatran on bleeding complications rates and INR monitoring will likely be factors in assessing its overall cost-effectiveness versus standard care.
Authors' methods: Overview
Details
Project Status: Completed
URL for project: https://www.ccohta.ca/
Year Published: 2003
English language abstract: An English language summary is available
Publication Type: Not Assigned
Country: Canada
MeSH Terms
  • Stroke
  • Thromboembolism
Contact
Organisation Name: Canadian Coordinating Office for Health Technology Assessment
Contact Address: 600-865 Carling Avenue, Ottawa, ON K1S 5S8 Canada. Tel: +1 613 226 2553, Fax: +1 613 226 5392;
Contact Name: jills@ccohta.ca
Contact Email: jills@ccohta.ca
Copyright: Canadian Coordinating Office for Health Technology Assessment (CCOHTA)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.